Skip to main content
SpringerLink
Log in

Genetics of fulminant type 1 diabetes

  • Mini-Review
  • Published:
Diabetology International Aims and scope Submit manuscript

Abstract

Since fulminant type 1 diabetes was reported as a distinct subtype of type 1 diabetes in 2000, the Committee on Type 1 diabetes, Japan Diabetes Society has continuously recruited patients and conducted genomic research to elucidate the genetic basis of fulminant type 1 diabetes. The contribution of the human leukocyte antigen complex (HLA) to genetic susceptibility to fulminant type 1 diabetes was compared with that of other subtypes in 2009. The alleles and haplotypes associated with fulminant type 1 diabetes were found to be different from acute-onset and slowly progressive type 1 diabetes. DRB1*15:01-DQB1*06:02, a protective haplotype against acute-onset type 1 diabetes, does not provide protection against fulminant type 1 diabetes and DRB1*08:02-DQB1*03:02, a susceptible haplotype to acute-onset type 1 diabetes, does not confer susceptibility to fulminant type 1 diabetes. Recently, the first genome-wide association study (GWAS) of fulminant type 1 diabetes was performed in Japanese individuals. A strong association was observed with multiple single nucleotide polymorphisms (SNPs) in the HLA region, and the strongest association was observed with rs9268853 in the class II DR region. In addition, 11 SNPs outside the HLA region showed some evidence of association with the disease. In particular, rs11170445 in CSAD/lnc-ITGB7-1 on chromosome 12q13.13 showed an association at a genome-wide significance level. Fine mapping revealed that rs3782151 in CSAD/lnc-ITGB7-1 showed the lowest P value. CSAD/lnc-ITGB7-1 was found to be strongly associated with susceptibility to fulminant, but not classical, autoimmune type 1 diabetes, implicating this locus in the distinct phenotype of fulminant type 1 diabetes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Imagawa A, Hanafusa T, Miyagawa J, Matsuzawa Y. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes related antibodies. Osaka IDDM study group. N Engl J Med. 2000;342(5):301–7.

    CAS  PubMed  Google Scholar 

  2. Imagawa A, Hanafusa T. Fulminant type 1 diabetes: a novel clinical entity requiring special attention by all medical practitioners. Nat Clin Prac Endocrinol Metab. 2007;3:36–45.

    Google Scholar 

  3. Gianani R, Eisenbarth GS. The stages of type 1A diabetes: 2005. Immunol Rev. 2005;204:232–49.

    CAS  PubMed  Google Scholar 

  4. Bakay M, Pandey R, Grant SFA, Hakonarson H. The genetic contribution to type 1 diabetes. Curr Diab Rep. 2019;19:116.

    CAS  PubMed  Google Scholar 

  5. Karvonen M, Viik-Kajander M, Moltchanova E, Libman I, LaPorte R, Tuomilehto J. Incidence of childhood type 1 diabetes worldwide. Diabetes mondiale (DiaMond) project group. Diabetes Care. 2000;23:1516–26.

    CAS  PubMed  Google Scholar 

  6. Ikegami H, Awata T, Kawasaki E, Kobayashi T, Maruyama T, Nakanishi K, Shimada A, Amemiya S, Kawabata Y, Kurihara S, Tanaka S, Kanazawa Y, Mochizuki M, Ogihara T. Japanese study group on type 1 diabetes genetics: the association of CTLA4 polymorphism with type 1 diabetes is concentrated in patients complicated with autoimmune thyroid disease: a multi-center collaborative study in Japan. J Clin Endocrinol Metab. 2006;91:1087–92.

    CAS  PubMed  Google Scholar 

  7. Ikegami H, Kawabata Y, Noso S, Fujisawa T, Ogihara T. Genetics of type 1 diabetes in Asian and Caucasian populations. Diabetes Res Clin Pract. 2007;77(Suppl. 1):S116–S12121.

    CAS  PubMed  Google Scholar 

  8. Cho YM, Kim JT, Ko KS, Koo BK, Yang SW, Park MH, Lee HK, Park KS. Fulminant type 1 diabetes in Korea: high prevalence among patients with adult-onset type 1 diabetes. Diabetologia. 2007;50:2276–9.

    CAS  PubMed  Google Scholar 

  9. Moreau C, Drui D, Arnault-Ouary G, Charbonnel B, Chaillous L, Cariou B. Fulminant type 1 diabetes in Caucasians: a report of three cases. Diabetes Metab. 2008;34:529–32.

    CAS  PubMed  Google Scholar 

  10. Rish N. Assessing the role of HLA-linked and unlinked determinants of disease. Am J Hum Genet. 1987;40:1–14.

    Google Scholar 

  11. Ikegami H, Oihara T. Genetics of insulin-dependent diabetes mellitus. Endocrine J. 1996;43:605–13.

    CAS  Google Scholar 

  12. Noble JA, Valdes AM, Cook M, Klitz W, Thomson G, Erlich HA. The role of HLA class II genes in insulin-dependent diabetes mellitus: molecular analysis of 180 Caucasian, multiplex families. Am J Hum Genet. 1996;59:1134–48.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Lambert AP, Gillespie KM, Thomson G, Cordell HJ, Todd JA, Gale EA, Bingley PJ. Absolute risk of childhood-onset type 1 diabetes defined by human leukocyte antigen class II genotype: a population-based study in the United Kingdom. J Clin Endocrinol Metab. 2004;89:4037–43.

    CAS  PubMed  Google Scholar 

  14. Todd J, Bell JI, MacDevitt HO. HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature. 1987;329:599–604.

    CAS  PubMed  Google Scholar 

  15. Ikegami H, Kawaguchi Y, Yamato E, Kuwata S, Tokunaga K, Noma Y, Shima K, Ogiharaet T. Analysis by the polymerase chain reaction of histocompatibility leukocyte antigen-DR9-linked susceptibility to insulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1992;75:1381–5.

    CAS  PubMed  Google Scholar 

  16. Kawabata Y, Ikegami H, Kawaguchi Y, Fujisawa T, Shintani M, Ono M, Nishino M, Uchigata Y, Lee I, Ogihara T. Asian-specific HLA haplotypes reveal heterogeneity of the contribution of HLA-DR and -DQ haplotypes to susceptibility to type 1 diabetes. Diabetes. 2002;51:545–51.

    CAS  PubMed  Google Scholar 

  17. Thomson G, Valdes AM, Noble JA, et al. Relative predispositional effects of HLA class II DRB1-DQB1 haplotypes and genotypes on type 1 diabetes: a meta-analysis. Tissue Antigens. 2007;70:110–27.

    CAS  PubMed  Google Scholar 

  18. Ikegami H, Noso S, Babaya N, Hiromine Y, Kawabata Y. Genetic basis of type 1 diabetes: similarities and differences between East and West. Rev Diabet Stud. 2008;5:64–72.

    PubMed  PubMed Central  Google Scholar 

  19. Kawabata Y, Ikegami H, Awata T, Imagawa A, Maruyama T, Kawasaki E, Tanaka S, Shimada A, Osawa H, Kobayashi T, Hanafusa T, Tokunaga K, Makino H. Committee on type 1 diabetes, Japan diabetes society. Diabetologia. 2009;52:2513–21.

    CAS  PubMed  Google Scholar 

  20. Tsutsumi C, Imagawa A, Ikegami H, Makino H, Kobayashi T, Hanafusa T. Japan diabetes society committee on type 1 diabetes mellitus research. Class II HLA genotype in fulminant type 1 diabetes: a nationwide survey with reference to glutamic acid decarboxylase antibodies. J Diabetes Investig. 2012;3:62–9.

    CAS  PubMed  Google Scholar 

  21. Imagawa A, Hanafusa T. Fulminant type 1 diabetes–an important subtype in East Asia. Diabetes Metab Res Rev. 2011;27:959–64.

    CAS  PubMed  Google Scholar 

  22. Kawabata Y, Nishida N, Awata T, Kawasaki E, Imagawa A, Shimada A, Osawa H, Tanaka S, Takahashi K, Nagata M, Yasuda H, Uchigata Y, Kajio H, Makino H, Yasuda K, Kobayashi T, Hanafusa T, Tokunaga K, Ikegami H. Genome-wide association study confirming a strong effect of HLA and identifying variants in CSAD/lnc-ITGB7–1 on chromosome 12q13.13 associated with susceptibility to fulminant type 1 diabetes. Diabetes. 2019;68:665–75.

    CAS  PubMed  Google Scholar 

  23. Evangelou M, Smyth DJ, Fortune MD, Burren OS, Walker NM, Guo H, Onengut-Gumuscu S, Chen W-M, Concannon P, Rich SR, Todd JA, Wallace C. A method for gene-based pathway analysis using genome wide association study summary statistics reveals nine new type 1 diabetes associations. Genet Epidemiol. 2014;38:661–70.

    PubMed  PubMed Central  Google Scholar 

  24. Sirdah MM. Protective and therapeutic effectiveness of taurine in diabetes mellitus: a rationale for antioxidant supplementation. Diabetes Metab Syndr. 2015;9:55–64.

    PubMed  Google Scholar 

  25. Lambert IH, Kristensen DM, Holm JB, Mortensen OH. Physiological role of taurine–from organism to organelle. Acta Physiol (Oxf). 2015;213:191–21212.

    CAS  Google Scholar 

  26. Huxtable RJ. Physiological actions of taurine. Physiol Rev. 1992;72:101–63.

    CAS  PubMed  Google Scholar 

  27. Marcinkiewicz J, Kontny E. Taurine and inflammatory diseases. Amino Acids. 2014;46:7–20.

    CAS  PubMed  Google Scholar 

  28. Kim C, Cha Y-N. Taurine chloramine produced from taurine under inflammation provides anti-inflammatory and cytoprotective effects. Amino Acids. 2014;46:89–100.

    CAS  PubMed  Google Scholar 

  29. Fakruddin M, Wei F, Suzuki T, et al. Defective mitochondrial tRNA taurine modification activates global proteostress and leads to mitochondrial disease. Cell Rep. 2018;22:482–96.

    CAS  PubMed  Google Scholar 

  30. Ohsawa Y, Hagiwara H, Nishimatsu S, et al. Taurine supplementation for prevention of stroke-like episodes in MELAS: a multicenter, open-label, 52-week phase III trial. J Neurol Neurosurg Psychiatry. 2019;90:529–36.

    PubMed  Google Scholar 

  31. Arany E, Strutt B, Romanus P, Remacle C, Reusens B, Hill DJ. Taurine supplement in early life altered islet morphology, decreased insulitis and delayed the onset of diabetes in non-obese diabetic mice. Diabetologia. 2004;47:1831–7.

    CAS  PubMed  Google Scholar 

  32. Lin S, Yang J, Wu G, Liu M, Lv Q, Yang Q, Hu J. Inhibitory effects of taurine on STZ-induced apoptosis of pancreatic islet cells. Adv Exp Med Biol. 2013;775:287–97.

    CAS  PubMed  Google Scholar 

  33. Volders PJ, Verheggen K, Menschaert G, Vandepoele K, Martens L, Vandesompele J, Mestdagh P. An update on LNCipedia: a database for annotated human lncRNA sequences. Nucleic Acids Res. 2015;43:D174–D180180.

    CAS  PubMed  Google Scholar 

  34. Westra HJ, Peters MJ, Esko T, et al. Systematic identification of trans eQTLs as putative drivers of known disease associations. Nat Genet. 2013;45:1238–43.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Narahara M, Higasa K, Nakamura S, Tabara Y, Kawaguchi T, Ishii M, Matsubara K, Matsuda F, Yamada R. Large-scale East-Asian eQTL mapping reveals novel candidate genes for LD mapping and the genomic landscape of transcriptional effects of sequence variants. PLoS ONE. 2014;9:e100924.

    PubMed  PubMed Central  Google Scholar 

  36. Higasa K, Miyake N, Yoshimura J, et al. Human genetic variation database, a reference database of genetic variations in the Japanese population. J Hum Genet. 2016;61:547–53.

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Berlin C, Berg EL, Briskin MJ, Andrew DP, Kilshaw PJ, Holzmann B, Weissman IL, Hamann A, Butcher EC. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell. 1993;74:185–95.

    CAS  PubMed  Google Scholar 

  38. Streeter PR, Berg EL, Rouse BT, Bargatze RF, Butcher EC. A tissue-specific endothelial cell molecule involved in lymphocyte homing. Nature. 1988;331:41–6.

    CAS  PubMed  Google Scholar 

  39. Hänninen A, Taylor C, Streeter PR, Stark LS, Sarte JM, Shizuru JA, Simell O, Michie SA. Vascular addressins are induced on islet vessels during insulitis in nonobese diabetic mice and are involved in lymphoid cell binding to islet endothelium. J Clin Invest. 1993;92:2509–15.

    PubMed  PubMed Central  Google Scholar 

  40. Faveeuw C, Gagnerault MC, Lepault F. Expression of homing and adhesion molecules in infiltrated islets of Langerhans and salivary glands of nonobese diabetic mice. J Immunol. 1994;152:5969–78.

    CAS  PubMed  Google Scholar 

  41. Yang XD, Sytwu HK, McDevitt HO, Michie SA. Involvement of beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in the development of diabetes in obese diabetic mice. Diabetes. 1997;46:1542–7.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank all of the participants in the project, the members of the Study Group on Type 1 Diabetes Genetics and the Committee on Type 1 diabetes, Japan Diabetes Society.

Author information

Authors and Affiliations

  1. Department of Endocrinology, Metabolism and Diabetes, Kindai University Faculty of Medicine, 377-2 Ohno-higashi, Osaka-sayama, Osaka, 589-8511, Japan

    Yumiko Kawabata & Hiroshi Ikegami

Authors
  1. Yumiko Kawabata
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroshi Ikegami
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yumiko Kawabata.

Ethics declarations

Conflict of interest

The authors have no financial conflicts of interest to disclose for this manuscript.

Ethics policy

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kawabata, Y., Ikegami, H. Genetics of fulminant type 1 diabetes. Diabetol Int 11, 315–322 (2020). https://doi.org/10.1007/s13340-020-00468-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13340-020-00468-0

Keywords

Search

Navigation